Literature DB >> 35748935

Correlation between change in central subfield thickness and change in visual acuity in macular edema due to retinal vein occlusion: post hoc analysis of COPERNICUS, GALILEO, and VIBRANT.

Sophie Z Gu1, Onnisa Nanegrungsunk2,3, Susan B Bressler2, Weiming Du4, Fouad Amer4, Hadi Moini4, Neil M Bressler5,6.   

Abstract

PURPOSE: Assess correlation between change in central subfield thickness (CST) and change in best-corrected visual acuity (BCVA) in eyes with macular edema due to retinal vein occlusion (RVO) that received intravitreal aflibercept injections (IAI).
METHODS: Post hoc analysis of COPERNICUS and GALILEO trials for CRVO and VIBRANT trial for BRVO with relationships determined using Pearson correlation coefficient.
RESULTS: In COPERNICUS, correlations (r) between change in CST and change in BCVA from baseline at weeks 12, 24, 52, and 100 were -0.36 (95% CI: -0.52, -0.18; P < 0.001), -0.38 (95% CI: -0.53, -0.20; P < 0.001), -0.44 (95% CI: -0.58, -0.27; P < 0.001), and -0.41 (95% CI: -0.56, -0.23; P < 0.001), respectively. CST changes accounted for only 21% of the variance in BCVA changes; every 100-µm decrease in CST was associated with a 2.1-letter increase in BCVA (P = 0.003). Similar findings were noted for GALILEO (r, -0.45 to -0.23) and VIBRANT (r, -0.36 to -0.32) trials.
CONCLUSION: In eyes treated with IAI for macular edema due to RVO, correlation between change in CST and change in BCVA was weak to moderate. While change in CST may be helpful in determining the need for anti-VEGF therapy, these findings do not support using changes in CST as a surrogate for changes in visual acuity outcomes.
© 2022. The Author(s).

Entities:  

Keywords:  Central subfield thickness; Macular edema; Retinal vein occlusion; Visual acuity

Year:  2022        PMID: 35748935     DOI: 10.1007/s00417-022-05697-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  15 in total

1.  Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.

Authors:  Yuichiro Ogura; Johann Roider; Jean-François Korobelnik; Frank G Holz; Christian Simader; Ursula Schmidt-Erfurth; Robert Vitti; Alyson J Berliner; Florian Hiemeyer; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink
Journal:  Am J Ophthalmol       Date:  2014-07-25       Impact factor: 5.258

2.  OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion.

Authors:  Alexandra Eva Hoeh; Mira Ruppenstein; Thomas Ach; Stefan Dithmar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-07-02       Impact factor: 3.117

Review 3.  Correlation Coefficients: Appropriate Use and Interpretation.

Authors:  Patrick Schober; Christa Boer; Lothar A Schwarte
Journal:  Anesth Analg       Date:  2018-05       Impact factor: 5.108

4.  Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.

Authors:  Jeffrey S Heier; W Lloyd Clark; David S Boyer; David M Brown; Robert Vitti; Alyson J Berliner; Husain Kazmi; Yu Ma; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink; Julia A Haller
Journal:  Ophthalmology       Date:  2014-03-27       Impact factor: 12.079

5.  Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.

Authors:  William C Ou; David M Brown; John F Payne; Charles C Wykoff
Journal:  Am J Ophthalmol       Date:  2017-05-24       Impact factor: 5.258

6.  Visual prognostic value of photopic negative response and optical coherence tomography in central retinal vein occlusion after anti-VEGF treatment.

Authors:  Chan Hee Moon; Sang Il Ahn; Young-Hoon Ohn; Hyung Woo Kwak; Tae Kwann Park
Journal:  Doc Ophthalmol       Date:  2013-03-15       Impact factor: 2.379

7.  Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.

Authors:  Richard F Spaide; Louis K Chang; James M Klancnik; Lawrence A Yannuzzi; John Sorenson; Jason S Slakter; K Bailey Freund; Robert Klein
Journal:  Am J Ophthalmol       Date:  2008-10-17       Impact factor: 5.258

8.  Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study.

Authors:  K Kriechbaum; S Michels; F Prager; M Georgopoulos; M Funk; W Geitzenauer; U Schmidt-Erfurth
Journal:  Br J Ophthalmol       Date:  2008-01-22       Impact factor: 4.638

9.  Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.

Authors:  W Lloyd Clark; David S Boyer; Jeffrey S Heier; David M Brown; Julia A Haller; Robert Vitti; Husain Kazmi; Alyson J Berliner; Kristine Erickson; Karen W Chu; Yuhwen Soo; Yenchieh Cheng; Peter A Campochiaro
Journal:  Ophthalmology       Date:  2015-10-30       Impact factor: 12.079

10.  Optical coherence tomography parameters predictive of visual outcome after anti-VEGF therapy for retinal vein occlusion.

Authors:  Akiko Fujihara-Mino; Yoshinori Mitamura; Naoki Inomoto; Hiroki Sano; Kei Akaiwa; Kentaro Semba
Journal:  Clin Ophthalmol       Date:  2016-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.